Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating its lead immunotherapy, EO2401, in recurrent glioblastoma
Read more
07
December 2022
Enterome presents two posters on Phase 2 data of its lead immunotherapy, EO2401, in recurrent glioblastoma (ROSALIE study) at ESMO IO 2022
Read more
16
November 2022
Enterome announces presentation of data from ongoing Phase 2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022
Read more
10
November 2022
Enterome’s OncoMimics™ peptide-based immunotherapy EO2401 generates and maintains elevated anti-tumor T cell responses for more than 10 months in patients with recurrent glioblastoma
Read more
07
November 2022
Enterome to present updated safety, immunogenicity and efficacy data from its Phase 1/2 trial of EO2401 in recurrent glioblastoma (ROSALIE study) at SITC 2022
Read more
11
October 2022
Enterome’s Management Attending Upcoming Meetings
Read more
16
September 2022
Enterome’s innovative OncoMimics™-based immunotherapy EO2401 distinguished with “Best Clinical Research Award” at EANO Meeting 2022 for promising results in recurrent gliobastoma
Read more
12
September 2022
Enterome presents further efficacy data on its new generation therapeutic cancer vaccine EO2401 at ESMO Congress, demonstrating ability of OncoMimics™ antigens to generate positive clinical outcome
Read more
06
September 2022
Enterome to present updates on EO2401, its first-in-class OncoMimics™ therapeutic cancer vaccine targeting solid tumors, at ESMO Congress 2022
